Constellium (CSTM) Q1 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2025 earnings summary
8 Jul, 2026Executive summary
Revenue rose 5% year-over-year to $2 billion in Q1 2025, driven by higher metal prices despite a 2% decline in shipments to 372,000 tons; net income increased to $38 million from $22 million, with adjusted EBITDA at $186 million, including a $46 million positive metal price lag and a $10 million negative impact from Valais flood recovery.
Free cash flow was negative $3 million, impacted by $27 million in flood-related costs at Valais; excluding these, free cash flow was $26 million.
1.4 million shares were repurchased for $15 million, with $206 million remaining in the program; leverage stood at 3.3x at quarter-end.
Safety performance was strong, with a recordable case rate of 1.02 per million hours worked, surpassing internal targets.
Financial highlights
Revenue reached $1,979 million in Q1 2025, up 5% from Q1 2024, primarily due to higher metal prices.
Net income was $38 million, up from $22 million year-over-year, with EPS at $0.26 versus $0.14.
Adjusted EBITDA was $186 million (including metal price lag), or $140 million excluding it; segment performance was mixed.
Free cash flow was negative $3 million, impacted by flood recovery costs; cash from operations improved to $58 million.
Share repurchases totaled $15 million (1.4 million shares) in the quarter.
Outlook and guidance
2025 guidance maintained: adjusted EBITDA (ex-metal price lag) of $600–$630 million and free cash flow over $120 million.
Long-term targets reaffirmed: adjusted EBITDA of $900 million and free cash flow of $300 million by 2028.
Guidance assumes stable macroeconomic and end-market conditions, with mitigating actions for tariffs.
Latest events from Constellium
- Q2 2024: Net income rose, cash flow strong, Swiss flooding paused guidance, 2025 target reaffirmed.CSTM
Q2 20248 Jul 2026 - Record Adjusted EBITDA and net income, with raised 2026 outlook and strong liquidity.CSTM
Q1 202629 Apr 2026 - Director appointments, executive pay, and share repurchase authorizations recommended for approval.CSTM
Proxy filing10 Apr 2026 - Shareholders will vote on director appointments, executive pay, financials, and share repurchases.CSTM
Proxy filing10 Apr 2026 - Shareholders to vote on director appointments, executive pay, and share repurchase plans after a strong 2025.CSTM
Proxy filing30 Mar 2026 - Record 2025 results, strong cash flow, reduced leverage, and Vision 2028 launched.CSTM
Q4 202518 Feb 2026 - Q3 2024 results were hit by lower volumes, flood losses, and weak demand across key markets.CSTM
Q3 202419 Jan 2026 - 2024 saw lower results from disruptions, but 2025–2028 targets reflect recovery and growth.CSTM
Q4 20246 Jan 2026 - 2025 guidance raised as revenue grows but net income declines on margin pressure.CSTM
Q2 202516 Nov 2025